In Brief: The Liposome Company TLC D-99
Executive Summary
The Liposome Company TLC D-99: Pfizer returns rights to the liposomal doxorubicin product to TLC on July 14; Pfizer will receive royalties on any sales of the product, which is in Phase III trials in metastatic breast cancer patients as a lower-cardiotoxicity alternative to conventional doxorubicin. TLC is attempting to reinvigorate its pipeline after the failure of its acute respiratory distress syndrome therapy Ventus in a Phase III trial ("The Pink Sheet" June 30, In Brief). TLC has let go of 110 employees, bringing its total headcount to about 300...